|
Post by jurystillout on Oct 1, 2015 18:58:54 GMT -5
Obviously, these layoffs are just part of a brilliant marketing strategy! Have no fear, mnkd/sny know exactly what they are doing and it's all part of a brilliant plan, do I really have to write a pumping novel to explain it to all of you? The JAC needs to get their act together and fix the obvious problems and actually come up with a plan for marketing, pricing, distribution and manufacturing plan. I thought incompetence like this was reserved for our government.
|
|
|
Post by nylefty on Oct 1, 2015 19:11:14 GMT -5
The layoffs are probably not a great concern in the big picture. For me, this is just another symptom of the underlying rot of incompetence and lack of setting and aggressive pursuit of goals.
If you threw in the towel why are you still here, whining about MNKD's management when the ball is now in Sanofi's court?
|
|
|
Post by jurystillout on Oct 1, 2015 19:37:19 GMT -5
Because with all of the incompetence of management I still have a tremendous amount of faith in the technology and science of technosphere and afrezza. I keep watching and hoping these two companies get their act together and do the right things to get this product moving. If they do I'll buy back in and win, if they don't we all lose however for me it won't be a financial loss. The ball isn't solely in sny court, The JAC is made up of equal representation from mnkd and sny and they are the ones that negotiate everything associated with affrezza, in my opinion the best things shareholders can do is to pressure management to do a better job. Their pay checks come from your investment(not mine) make them earn it!
|
|
|
Post by od on Oct 1, 2015 20:29:35 GMT -5
Because with all of the incompetence of management I still have a tremendous amount of faith in the technology and science of technosphere and afrezza. I keep watching and hoping these two companies get their act together and do the right things to get this product moving. If they do I'll buy back in and win, if they don't we all lose however for me it won't be a financial loss. The ball isn't solely in sny court, The JAC is made up of equal representation from mnkd and sny and they are the ones that negotiate everything associated with affrezza, in my opinion the best things shareholders can do is to pressure management to do a better job. Their pay checks come from your investment(not mine) make them earn it! Truly not a challenge question - Have you launched a new therepeutic modailty (even one with labeling that allowed superiority claims, which Afrezza does not currently enjoy)? If yes, please share an overview of your marketing strategy and tactics. I won't argue that mistakes have been made.
|
|
|
Post by pengiep on Oct 1, 2015 20:44:37 GMT -5
Why should MNKD management care what the banksters are stealing? Our MNKD "management" are making their fat stacks of cash anyway. When someone can explain what it is they are doing for their money, please let me know.
|
|
|
Post by harrys on Oct 1, 2015 20:47:37 GMT -5
Why should MNKD management care what the banksters are stealing? Our MNKD "management" are making their fat stacks of cash anyway. When someone can explain what it is they are doing for their money, please let me know. Maybe they're sitting back at their desks, feet up, browsing pornhub while counting their "fat stacks". I can only hope my investment dollars have gone to such a charitable purpose...
|
|
|
Post by pengiep on Oct 1, 2015 20:55:14 GMT -5
After my experience with MNKD, I wouldn't touch EYES with a 10' pole. At this point, I wouldn't invest in another Mann company even with someone else's money. The science behind TechnoSphere and Afrezza is beyond reproach. If it doesn't sell like crazy, what makes anyone think EYES, with much less biomedical credibility than Afrezza, has a snowball's chance?
|
|
|
Post by savzak on Oct 1, 2015 21:18:59 GMT -5
After my experience with MNKD, I wouldn't touch EYES with a 10' pole. At this point, I wouldn't invest in another Mann company even with someone else's money. The science behind TechnoSphere and Afrezza is beyond reproach. If it doesn't sell like crazy, what makes anyone think EYES, with much less biomedical credibility than Afrezza, has a snowball's chance? Good point. EYES is logically if not physically bound to follow the exact same path as MNKD. How could that not be the case with them both being founded by the same person?
|
|
|
Post by jurystillout on Oct 1, 2015 21:34:00 GMT -5
Because with all of the incompetence of management I still have a tremendous amount of faith in the technology and science of technosphere and afrezza. I keep watching and hoping these two companies get their act together and do the right things to get this product moving. If they do I'll buy back in and win, if they don't we all lose however for me it won't be a financial loss. The ball isn't solely in sny court, The JAC is made up of equal representation from mnkd and sny and they are the ones that negotiate everything associated with affrezza, in my opinion the best things shareholders can do is to pressure management to do a better job. Their pay checks come from your investment(not mine) make them earn it! Truly not a challenge question - Have you launched a new therepeutic modailty (even one with labeling that allowed superiority claims, which Afrezza does not currently enjoy)? If yes, please share an overview of your marketing strategy and tactics. I won't argue that mistakes have been made. You've got me there, I've never "launched a new therepeutic modality", however I have built 4 business's from the ground-up that each generate 7 figure profits each year, two of these four are specific to the medical field. My questions to you are- Are you really happy with the amount of effort sny has put forth to move this product? Looking at what has been done in the last year do you really believe selling affrezza is a high priority for sny? Knowing that sny has "launched new therepeutic modalities" before wouldn't you expect them to have been able to foresee some of the potential problems and avoid these mistakes you mentioned, members of this board addressed potential issues before they happened, spirometer testing, educating physicians, insurance reimbursements... why didn't sny see this coming and address them in advance? Incompetence is the only way I can describe what I've seen. However you are correct, they are not using my money to make payroll so I will refrain posting my opinion about how they spend your money.
|
|
|
Post by afrizzle on Oct 1, 2015 22:09:25 GMT -5
Lots of tension here, but really no change to the value prop
The only way anyone's getting my shares is to pry them from my cold dead hands
|
|
|
Post by od on Oct 1, 2015 22:41:07 GMT -5
Truly not a challenge question - Have you launched a new therepeutic modailty (even one with labeling that allowed superiority claims, which Afrezza does not currently enjoy)? If yes, please share an overview of your marketing strategy and tactics. I won't argue that mistakes have been made. You've got me there, I've never "launched a new therepeutic modality", however I have built 4 business's from the ground-up that each generate 7 figure profits each year, two of these four are specific to the medical field. My questions to you are- Are you really happy with the amount of effort sny has put forth to move this product? Looking at what has been done in the last year do you really believe selling affrezza is a high priority for sny? Knowing that sny has "launched new therepeutic modalities" before wouldn't you expect them to have been able to foresee some of the potential problems and avoid these mistakes you mentioned, members of this board addressed potential issues before they happened, spirometer testing, educating physicians, insurance reimbursements... why didn't sny see this coming and address them in advance? Incompetence is the only way I can describe what I've seen. However you are correct, they are not using my money to make payroll so I will refrain posting my opinion about how they spend your money. Pharmaceutical companies have commercial teams developing product introduction plans years prior to launch. Imagine if Afrezza had the best possible labeling from day 1. Providers would be excited, payors would be excited, patients would be excited (especially with no resistance from providers or payors). How could uptake not be metered by lack of data and coverage? I am not making excuses for SNY. My big concern at launch was meager spirometer penetration and I believe SNY was too cavalier about how it might hamper NRxs. If SNY gets it done over the next 24 months, I am confident the total return on 'my money' will be more than respectable.
|
|
|
Post by Chris-C on Oct 2, 2015 8:13:37 GMT -5
You've got me there, I've never "launched a new therepeutic modality", however I have built 4 business's from the ground-up that each generate 7 figure profits each year, two of these four are specific to the medical field. My questions to you are- Are you really happy with the amount of effort sny has put forth to move this product? Looking at what has been done in the last year do you really believe selling affrezza is a high priority for sny? Knowing that sny has "launched new therepeutic modalities" before wouldn't you expect them to have been able to foresee some of the potential problems and avoid these mistakes you mentioned, members of this board addressed potential issues before they happened, spirometer testing, educating physicians, insurance reimbursements... why didn't sny see this coming and address them in advance? Incompetence is the only way I can describe what I've seen. However you are correct, they are not using my money to make payroll so I will refrain posting my opinion about how they spend your money. Pharmaceutical companies have commercial teams developing product introduction plans years prior to launch. Imagine if Afrezza had the best possible labeling from day 1. Providers would be excited, payors would be excited, patients would be excited (especially with no resistance from providers or payors). How could uptake not be metered by lack of data and coverage? I am not making excuses for SNY. My big concern at launch was meager spirometer penetration and I believe SNY was too cavalier about how it might hamper NRxs. If SNY gets it done over the next 24 months, I am confident the total return on 'my money' will be more than respectable. od: Thanks for your post. It was a good one, IMO. You are correct. This story could have gone differently if not for several key developments that have happened to MNKD during their journey so far. It is tough sledding to launch a new drug to begin with, much less a novel, paradigm changing treatment that challenges the status quo and threatens the market share of some established pharmaceutical powerhouses. When one adds the unexplained shenanigans of the FDA and the questionable tactics of AF, Shkreli, and hedge fund managers promising the drug will go to $1.00, it's been clear that the task was not going to be like a day at the beach. Yet, knowing these hurdles, it seems to remain fashionable for people to bash the company and the leadership team for failing to work magic. I don't understand this, since it is not possible for us to actually know what the precise gameplan is, the timetable, and how results are matching with expectations. We do know that the uptake has gone slower than expected; and most understand that the primary barriers are the label, (which restricts marketing the drug for its known benefits); insurance coverage, (which forces delays and denials or requires large copays), and spirometry testing, (which adds a layer of inconvenience to providers and diabetics alike). This is all unfortunate, but it's the story we're in, and we each can choose to react with frustration by bashing the company or by being realistic and patient with allowing the process and the players a reasonable timeframe to demonstrate a path to success. I expect it will take several more months at the least. There is no consensus here on how much time should be given; but many share the view that significant improvements in weekly script numbers should become evident by year's end. The trouble with our digital Instagram society is that some social systems still work according to analog time frames. And time is an ally in the devil's workshop for shorts and others hoping the company goes bankrupt. The very idea that some people are ok with making money by denying lifesaving technology to others is obscene. But that is the way it is in today's very messed up world. GLTAL Chris C
|
|
|
Post by kball on Oct 2, 2015 8:25:04 GMT -5
I will be buying more when I get back from my Hawaii vacation. Time zone and spotty Internet make it hard to buy at stock, so I will wait until I am back on the mainland. If I miss my chance for the lowest price then so be it. I will be also, but I am not Hawaii. I'm thinking of "selling" 5 shares to buy one of those blue travel books on hawaii w lots of pictures! And dream.
|
|
|
Post by jay1ajay1a on Oct 2, 2015 9:12:19 GMT -5
I wish we could have a serious discussion on what we think Al would or could take the company private for, based on past experience investing? or experience in the private sector? $5 is my break even and considering the lack of opportunity cost in the broader market in the timeframe I've been invested, I wouldn't stand in Al's way if he went for >$5. I'll wash my hands off this trainwreck for 4.50$ If the tiny sample size of this board is able to price MNKD at 4.50, imagine what the real market will do to this company? I throw in my towel today. There is no redemption for this stock or the company. As far as I am concerned, Al Mann stole my money.I think we all feel this way and wish I just started to buy the this stock. I have over 40K shares at around $4.40 per share. I still feel it is a good stock and will be buying more. No one stole our money, and I do not like were the price is. We will know in the next few months if this will pan out and I think it will. We need TRx to start moving up and I believe we will be over 1,000 TRx in 8 weeks.
|
|
|
Post by od on Oct 2, 2015 19:57:48 GMT -5
Pharmaceutical companies have commercial teams developing product introduction plans years prior to launch. Imagine if Afrezza had the best possible labeling from day 1. Providers would be excited, payors would be excited, patients would be excited (especially with no resistance from providers or payors). How could uptake not be metered by lack of data and coverage? I am not making excuses for SNY. My big concern at launch was meager spirometer penetration and I believe SNY was too cavalier about how it might hamper NRxs. If SNY gets it done over the next 24 months, I am confident the total return on 'my money' will be more than respectable. od: Thanks for your post. It was a good one, IMO. You are correct. This story could have gone differently if not for several key developments that have happened to MNKD during their journey so far. It is tough sledding to launch a new drug to begin with, much less a novel, paradigm changing treatment that challenges the status quo and threatens the market share of some established pharmaceutical powerhouses. When one adds the unexplained shenanigans of the FDA and the questionable tactics of AF, Shkreli, and hedge fund managers promising the drug will go to $1.00, it's been clear that the task was not going to be like a day at the beach. Yet, knowing these hurdles, it seems to remain fashionable for people to bash the company and the leadership team for failing to work magic. I don't understand this, since it is not possible for us to actually know what the precise gameplan is, the timetable, and how results are matching with expectations. We do know that the uptake has gone slower than expected; and most understand that the primary barriers are the label, (which restricts marketing the drug for its known benefits); insurance coverage, (which forces delays and denials or requires large copays), and spirometry testing, (which adds a layer of inconvenience to providers and diabetics alike). This is all unfortunate, but it's the story we're in, and we each can choose to react with frustration by bashing the company or by being realistic and patient with allowing the process and the players a reasonable timeframe to demonstrate a path to success. I expect it will take several more months at the least. There is no consensus here on how much time should be given; but many share the view that significant improvements in weekly script numbers should become evident by year's end. The trouble with our digital Instagram society is that some social systems still work according to analog time frames. And time is an ally in the devil's workshop for shorts and others hoping the company goes bankrupt. The very idea that some people are ok with making money by denying lifesaving technology to others is obscene. But that is the way it is in today's very messed up world. GLTAL Chris C Thanks Chris. Interesting that you reference our digital society. I often think about how it influences (corrupts?) expectations. We trade on a whim, educate ourselves ad nauseum, and since almost everything is at our keystroke fingertips, expect instant gratification. If Pfizer's pre-digital age (OK, emerging digital-age) Zithromax launch took place today, the 'they are idiots' board noise would be deafening. Acknowledging that mistakes were made (and they probably won't be the last) I trust the professionals at SNY are committed to Afrezza's success. (Call me old fashion.)
|
|